Part 9 of 10
Can these treatments trigger mania?
In a person with bipolar disorder, any treatment that lifts depression can sometimes tip mood into mania. This is called a switch. It is uncommon, and it is disruptive when it happens, so we take it seriously.
In controlled studies of TMS, switches were no more common with real treatment than with sham treatment. Small controlled studies of ketamine found the same.
Spravato has not yet been tested against placebo in bipolar disorder. Real-world reports from the first weeks of treatment are reassuring. Over months of ongoing treatment, some people with bipolar disorder have had manic symptoms, which is why follow-up continues.
The evidence
Evidence mixed
Across 53 randomized trials of TMS for depression, treatment-emergent mania or hypomania occurred in 0.84% of active and 0.73% of sham patients, a difference that was not statistically significant. In sham-controlled trials limited to bipolar depression, a switch occurred in 1 of 106 active and 1 of 75 sham patients.
In a placebo-controlled crossover trial of ketamine added to lithium or valproate, one participant developed manic symptoms on ketamine and one on placebo. These trials were small and enrolled people who were already taking a mood stabilizer and had no manic symptoms at entry.
A systematic review of ketamine in bipolar depression counted hypomanic or manic symptoms in 6 of 235 participants (about 2%) across 8 studies, most of them uncontrolled. In one repeated-infusion study, 4 of 66 participants had a hypomanic switch.
For esketamine, a naturalistic study of 35 people with bipolar treatment-resistant depression found no treatment-emergent switch. In a real-world cohort of 45 people given ketamine or esketamine, none switched during the first four weeks, and 13 (29%) had hypomanic or manic symptoms at some point during maintenance, one of them needing hospital care. A large records-based comparison of 2,126 matched patients found no higher switch risk with esketamine plus a mood stabilizer than with a mood stabilizer alone; that study was observational.
- Xia et al. 2008, Int J Neuropsychopharmacology (mania in TMS trials)
- McGirr et al. 2016, Bipolar Disorders (TMS in bipolar depression)
- Diazgranados et al. 2010, Arch Gen Psychiatry (ketamine in bipolar depression)
- Fancy et al. (ketamine for bipolar depression, systematic review)
- Martinotti et al., REAL-ESK Study Group (esketamine in bipolar treatment-resistant depression)
- Santucci et al. (ketamine and esketamine in bipolar depression, real-world cohort)